483
Samsung Biologics Co., Ltd.Samsung Biologics Co., Ltd. – FDA 483, Jun 26, 2018
Record Details
An FDA inspection of Samsung Biologics Co. Ltd. in Yeonsu, Incheon, a sterile drug manufacturer, revealed significant deficiencies across three observations. The firm was cited for inadequate training of visual inspectors, issues with equipment design and calibration records, and insufficient detail in cleaning and maintenance procedures for critical surfaces. These findings indicate a need for improved quality control and adherence to good manufacturing practices.
View Company Profile
ID · f30ce007-aebc-4adb-b5d0-3fe2fcb25da0
Other documents for Samsung Biologics Co., Ltd.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.